{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:55Z","timestamp":1786988995682,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:13:02Z","timestamp":1746173582000},"page":"941-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial"],"prefix":"10.1016","volume":"8","author":[{"given":"Petros","family":"Grivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Climent Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Kopyltsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Tyroller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Manitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.004_b0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11934-018-0858-0","article-title":"Patient-centered outcomes in bladder cancer","volume":"19","author":"Gore","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euo.2025.04.004_b0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s41687-019-0141-2","article-title":"Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy","volume":"3","author":"Taarnh\u00f8j","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.euo.2025.04.004_b0015","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm10091852","article-title":"Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo- or immunotherapy: a real-life experience","volume":"10","author":"Taarnh\u00f8j","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2025.04.004_b0020","first-page":"1383","article-title":"Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer","volume":"21","author":"Singer","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.euo.2025.04.004_b0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bju.14047","article-title":"Impact of bladder cancer on health-related quality of life","volume":"121","author":"Smith","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.04.004_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.urolonc.2018.12.006","article-title":"Mental health implications in bladder cancer patients: a review","volume":"37","author":"Pham","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.004_b0040","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer v5. 2024."},{"key":"10.1016\/j.euo.2025.04.004_b0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0050","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0055","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.004_b0060","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.004_b0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00031305.1995.10476135","article-title":"Comparing treatments using quality-adjusted survival: the Q-TWiST method","volume":"49","author":"Gelber","year":"1995","journal-title":"Am Stat"},{"key":"10.1016\/j.euo.2025.04.004_b0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/pon.3595","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer","volume":"24","author":"Tate","year":"2015","journal-title":"Psychooncology"},{"key":"10.1016\/j.euo.2025.04.004_b0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euo.2025.04.004_b0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737167.2018.1434414","article-title":"Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology","volume":"18","author":"Solem","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.euo.2025.04.004_b0085","first-page":"86","article-title":"Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index","volume":"11","author":"Jensen","year":"2013","journal-title":"J Support Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0090","doi-asserted-by":"crossref","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"10.1016\/j.euo.2025.04.004_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40271-024-00709-3","article-title":"Patient preferences for first-line treatment of locally advanced or metastatic urothelial carcinoma: an application of multidimensional thresholding","volume":"18","author":"Apolo","year":"2025","journal-title":"Patient"},{"key":"10.1016\/j.euo.2025.04.004_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4502","article-title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euf.2024.03.005","article-title":"Front-line platinum continues to have a role in advanced bladder cancer","volume":"10","author":"Vogl","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.04.004_b0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2024.02.010","article-title":"The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma?","volume":"7","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2047","article-title":"Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma","volume":"35","author":"Bedke","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.004_b0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2022.06.007","article-title":"Time to rethink quality of life assessment in patients with urothelial cancer in the current therapeutic era?","volume":"83","author":"Bergerot","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:19:49Z","timestamp":1758079189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125000987"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}